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Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which transduces cytokine and
growth factor signalling. Analysis of TYK2 loss-of-function revealed its important role in immunity to
infection, (auto-) immunity and (auto-) inflammation. TYK2-deficient patients unravelled high similarity
between mice and men with respect to cellular signalling functions and basic immunology. Genome-
wide association studies link TYK2 to several autoimmune and inflammatory diseases as well as carcino-
genesis. Due to its cytokine signalling functions TYK2 was found to be essential in tumour surveillance.
Lately TYK2 activating mutants and fusion proteins were detected in patients diagnosed with leukaemic
diseases suggesting that TYK2 is a potent oncogene. Here we review the cell intrinsic and extrinsic func-
tions of TYK2 in the characteristics preventing and enabling carcinogenesis. In addition we describe an
unexpected function of kinase-inactive TYK2 in tumour rejection.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The non-receptor tyrosine kinase 2 (TYK2) is a member of the
Janus kinase (JAK) family consisting of three additional members
(JAK1-3). Cytokine binding to and activation of the respective
receptor complexes activate JAKs by auto- or trans-
phosphorylation. Subsequently JAKs phosphorylate intracellular
receptor chain residues and activate a family of transcription fac-
tors termed signal transducers and activators of transcription
(STATs, comprised of STAT1-4, STAT5A, STAT5B and STAT6). Phos-
phorylated STATs re-orientate in their homo- or heterodimeric
conformation and translocate into the nucleus to induce specific
gene transcription. The resulting gene expression program drives
various cellular mechanisms like proliferation, differentiation or
death [1,2]. TYK2 was the first JAK family member genetically
linked to cytokine, i.e. interferon (IFN) responses [3]. Further anal-
yses of mutant human cells unresponsive to cytokines revealed
that all JAKs are major players in signal transduction of cytokines
[4–7]. Today it is well established that defined combinations of
mono- or multimeric cytokine receptor complexes associated with
JAKs and STATs drive the response to cytokines and growth factors
[8,9].
The JAK–STAT pathway is evolutionary highly conserved [10].
The most ancient TYK2 orthologs have been identified in fish
[11,12]. Gene targeted mice determined the in vivo loss-of-
function (LOF) phenotypes for the Jak loci. In contrast to the lethal-ity of lack of JAK1 and JAK2 [13–15] and the severe combined
immunodeficiency of lack of JAK3 [16,17], TYK2 LOF does not lead
to pathology under conventional housing conditions. Only upon
immunological challenges Tyk2/ mice show pathological pheno-
types. Tyk2-deficient mice have been reported by three different
groups [18–20]. Additionally, a naturally occurring TYK2 mutant
B10.D1-H2q/SgJ mouse strain has been discovered [21]. Recently
further naturally occurring mutations in SJL/J and SWR/J mouse
strains resulting in reduced TYK2 expression have been identified
[22]. A floxed mouse model (Tyk2fl/fl) allows cell type-specific dele-
tion of TYK2 [23]. It becomes increasingly evident that JAKs display
functions, which are independent of their enzymatic activity and/
or receptor association. Both mouse and human TYK2 have been
shown to exert these non-canonical functions [24–27]. The gener-
ation of a kinase-inactive TYK2 mouse (Tyk2K923E) enables the
investigation of non-canonical TYK2 in vivo [28]. The data from
TYK2 LOF and mutant patients increase constantly and underscore
the validity of the murine models for the translation into human
pathophysiology and clinical settings [29–32].
The biological role of TYK2 has been mainly established in the
context of host responses to infectious agents and of (auto-)
immune or (auto-)inflammatory diseases [25]. The importance of
TYK2 in tumour immunosurveillance has been also established
[33]. While the role for other JAKs as drivers in the development
of cancer has been intensively studied since many years, the signif-
icance of cell intrinsic TYK2 in oncogenesis has been revealed only
recently [34,35].
In this review we will shortly recapitulate the structural fea-
tures of TYK2 and its established functions in immunity andoi.org/
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involvement in tumour surveillance and carcinogenesis.
2. TYK2 structure, stability and post-translational modifications
TYK2 has been identified more than 25 years ago [36,37]. It is
located on chromosome 19 in humans and chromosome 9 in mice.
TYK2, as the other JAKs, is a relatively large protein with a molec-
ular weight of 130 kDa. The sequence homology organizes JAKs
into seven JAK homology (JH) domains 1–7 [38]. Structurally JAKs
consist of four different domains: the N-terminal 4.1, Ezrin,
Radixin, Moesin (FERM) domain, the Src homology 2 (SH2) domain,
the pseudokinase domain and the C-terminal kinase domain
[38,39] (see Fig. 1). The FERM domain (JH7-5 and a part of JH4)
mediates stable association of JAKs with receptor domains. So far
only shown for JAK2 and JAK3 it is also involved in kinase activityFig. 1. Schematic TYK2 structure, post-translational modification and mutation sites of T
from JAK homology (JH) domain 1–7 indicated on top. The amino acid scale of human TY
Phosphorylation (dark blue) and ubiquitination (light blue) sites in human TYK2 (top) and
occurring and induced amino acid variants along TYK2 are depicted for humans (top
Mutations resulting in catalytically inactive or impaired TYK2 variants are depicted in b
with so far unknown consequences are illustrated in grey.
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involved in receptor binding [42]. The pseudokinase domain
(JH2) has a canonical kinase domain that lacks catalytical function
despite binding ATP [43] and is important for regulating the activ-
ity of the kinase domain [39,44]. Interestingly, the JAK pseudoki-
nase domain is frequently mutated in human cancer patients
[39,44]. The C-terminal kinase domain (JH1) harbours the catalyt-
ically active kinase with the two conserved tyrosine residues in the
activation loop (see below). So far the molecular mechanism how
the JAK pseudokinase regulates the activity of the kinase domain
is not fully understood. A recent crystal structure of the kinase/
pseudokinase domains of TYK2 indicates that the pseudokinase
domain exerts an autoinhibitory function on the kinase domain,
which becomes activated upon receptor dimerization [45,46]. Acti-
vation of TYK2 occurs by phosphorylation at Y1054/Y1055 in
humans and Y1047/Y1048 in mice [25] (see Fig. 1). Several otherYK2 in mice and men. Upper panel. TYK2 consists of four structural domains ranging
K2 is depicted; murine TYK2 is 1180 aa (www.uniprot.org) in length. Middle panel.
orthologous residues in murine TYK2 (below) are indicated. Lower panel. Naturally
, see Refs. [46,99,106,191,193,199–202]) and mice (bottom, see Refs. [21,22,28]).
lue, catalytically hyperactive TYK2 variants are shown in pink. Missense mutations
ant of tumours and bona fide oncogene, Cytokine (2015), http://dx.doi.org/
Table 1
Cytokines activating TYK2 in association with the respective receptor chains.
Cytokine
receptor
family
Cytokine/growth
factor
Receptor chain(s)
associated with
TYK2
Receptor chain(s)
associated with other
JAKs
Class I cytokine receptors
gp130
receptor
family
IL-6 gp130/TYK2 IL-6Ra/JAK1,2
IL-11 gp130/TYK2 IL-11Ra/JAK1,2
CT-1, CLC gp130/TYK2 LIFR/JAK1,2
CNTF gp130/TYK2 CNTFR/JAK1,2
LIF gp130/TYK2 LIFR/JAK1,2
OSM gp130/TYK2 OSMR/JAK1,2
IL-27 gp130/JAK1, TYK2 IL-27R/JAK2
IL-12
receptor
family
IL-12 IL12-Rb1/TYK2 IL12-Rb2/JAK2
IL-23 IL12-Rb1/TYK2 IL-23R/JAK2
IL-13
receptors
IL-13 IL-13Ra/TYK2 IL-4Ra/JAK1
Class II cytokine receptors
IFN type I
receptors
Mainly IFNas and
IFNb
IFNAR1/TYK2 IFNAR2/JAK1
IL-10
receptor
family
IL-10 IL-10R2/TYK2 IL-10R1/JAK1
IL-22 IL-10R2/TYK2 IL-22R1/JAK1
IL-26 IL-10R2/TYK2 IL-20Ra/JAK1
IFN type III
receptors
IFNk1-4 IL10-R2/TYK2 IL28R1/JAK1
Note that we have grouped the cytokines according to their receptor chain com-
positions. Classification according to the cytokine families would include for the IL-
6 family IL-31; for the IL-12 family IL-27 and IL-35; for the IL-10 family the sub-
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undergo phosphorylation on serine or tyrosine, but so far their
function is unknown [47–52]. For JAK2 phosphorylation of residues
Y119 (FERM domain), S523 and Y570 (SH2/pseudokinase domains)
have negative regulatory effects, while phosphorylation of Y813
(pseudokinase domain) has positive regulatory effects [39,53]. So
far, no orthologous phosphorylated residues have been identified
in TYK2. One case of ubiquitination has so far been identified for
TYK2 [54], whereas SUMOylation has only been reported for
JAK2 [55] (see Fig. 1). The functions of the posttranslational modi-
fications outside the activation loop are grossly unknown. Equally
unknown are the turnover rates of TYK2 in vivo in different tissues
and under different activity and/or posttranslational modified
states. Early in vitro studies determined an intermediate half-life
of TYK2 upon stimulation of approximately two hours [56]. The
heat shock family member HSP90 was found to interact with
TYK2 thereby stabilizing it [57,58]. Recently pharmaceutical tar-
geting of HSP90 was identified as promising cancer therapy
because HSP90 inhibitors lead to degradation of wildtype and con-
stitutively active mutant TYK2 with subsequent impairment of sig-
nalling in cell lines and patient samples [59].
C-terminal structure analysis of TYK2 is of high priority because
this enables identification of inhibitory molecules [60,61]. Never-
theless additional efforts are required to elucidate the full-length
structure of TYK2 (ideally bound to a paradigm receptor) and the
imaging-based analysis of TYK2 activities; proof of methodological
feasibility has been provided for JAK1 and JAK2 [62,63]. The power
of mass spectrometry combined with in vitro/in vivo gene editing
[64,65] should be used to decipher the biological significance of
the post-translational modifications of TYK2.families IL-20 (including IL-19, IL-22, IL-24; IL-26) and the more distantly related IL-
28 and IL-29 (aka IFNk).3. Cytokine signalling via TYK2 and (de-)activation of TYK2
TYK2 is expressed ubiquitously and has been shown to be asso-
ciated with five different receptor chains: IFN a receptor 1
(IFNAR1), interleukin (IL) 10 receptor 2 (IL-10R2), IL-12 receptor
b1 (IL-12Rb1), IL-13 receptor a1 (IL-13Ra1) and gp130. JAK1 or
JAK2, but never JAK3 are associated to the corresponding second
receptor chain of the receptor complex [25] (see Table 1). Accord-
ingly TYK2 is activated, i.e. phosphorylated on the JH1 domain tyr-
osine residues, upon binding of type I IFNs (IFNas, IFNb and others,
see [66,67]), the IL-10/IL-20 (sub)families of cytokines [68,69], the
IL-12 family [70], IL-4/IL-13 [71,72] and the IL-6/gp130 family of
cytokines [73,74] to the cognate receptor complexes. The depen-
dence of the cellular responses on TYK2 may vary between differ-
ent cytokines/growth factors and also between mice and men. In
summary, data accumulated from LOF of TYK2 cells show profound
contributions of TYK2 to signalling of type I and III IFNs, IL-12, IL-
13, IL-22, and IL-23 [25,75–79]. For the IL-6 family members and
IL-10 the biological significance of TYK2 is neglectable or unclear
[25,80].
JAKs are negatively regulated by phosphatases and SOCS (sup-
pressors of cytokine signalling) [39]. Expression of SOCS family
members is induced via the JAK–STAT pathway in order to act as
a negative feedback loop [81,82]. Recently, transcellular delivery
of SOCS in exosomes has been reported as alternative counter-
regulatory mechanism [83]. SOCS proteins exert their functions
by induction of degradation of JAK-associated receptor complexes
[84]. Out of the 8 SOCS family members SOCS1 and SOCS3 were
shown to inhibit TYK2 [85–89]. Src homology 2 domain containing
protein tyrosine phosphatase (SHP) 1 directly interacts with TYK2
[90,91]. Protein tyrosine phosphatase (PTP) 1B effectively binds to
TYK2 and increased PTP1B inhibits IFN signalling [92,93]. Finally,
CD45 is reported to dephosphorylate all JAK family members [94].Please cite this article in press as: N.R. Leitner et al., Tyrosine kinase 2 – Surveill
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Many studies utilizing LOF mice revealed the importance of
TYK2 in disease with either harmful or beneficial effects. TYK2 is
required for immunity to microbial infections mainly through
transducing signals of type I IFNs and IL-12. On the other hand
TYK2 is detrimental in (auto-) inflammatory and/or (auto- or
chronic) immune diseases through amplification and/or prolonga-
tion of cytokine responses (for a review see [25]).
In 2006 the first patient with a homozygous TYK2 deletion
resulting in loss of TYK2 due to a premature stop codon at aa 90
has been described [31]. The patient was diagnosed with autoso-
mal recessive (AR) hyper IgE syndrome (HIES) and suffered from
viral, fungal and mycobacterial infections. Screening of other HIES
patients revealed that TYK2 deficiency is not a common cause of
HIES [95,96]. The patient’s cells showed impaired signalling of type
I IFN, IL-6, IL-10, IL-12 and IL-23. Subsequently seven TYK2-
deficient patients were identified suffering from viral and/or
mycobacterial infections but not from HIES, candidiasis or inflam-
matory diseases. In-depth analyses of signalling pathways and
cytokine production profiles showed impaired but not abolished
responses to all TYK2 activating cytokines (see Table 1) except to
IL-6 [29,30,32].
Several genome-wide association studies (GWAS) emerged in
the recent years linking TYK2 to autoimmune and inflammatory
diseases [97]. TYK2 polymorphisms have been associated with sys-
temic lupus erythematosus (SLE) [98–102], multiple sclerosis (MS)
[103–105], systemic sclerosis (SSc) [106] rheumatoid arthritis (RA)
[99,107], Crohn’s disease (CD) and ulcerative colitis (UC) [108,109],
psoriasis [107], type I diabetes [110–112], primary biliary cirrhosis
(PBC) [113] and idiopathic inflammatory myopathies (IIM) [114].ant of tumours and bona fide oncogene, Cytokine (2015), http://dx.doi.org/
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phisms (SNPs) are causative for or only correlated to these
diseases.5. TYK2 in cancer
After the initial reports of mutations in the last century the
JAK–STAT pathway gained highest attention through the discovery
of the activating JAK2V617F mutation causing myeloproliferative
diseases in 2005 [115–118]. Since then next generation sequencing
(NGS) led to the rapid identification of many more JAK–STAT muta-
tions. The data revealed that the JAK–STAT pathway is among the
most mutated signal transduction pathways in cancer and therefor
was coined by Bert Vogelstein as one of the 12 core cancer path-
ways [119]. Not only does JAK–STAT contribute to most if not all
hallmarks of cancer [120–124], it also acts in a cell type-specific
and mutational context-dependent fashion to display tumour sup-
pressive as well as oncogenic properties. In the following we sum-
marize the known contributions of TYK2 to the hallmarks and
enabling characteristics of cancer (see Table 2) [122,125].
5.1. ‘Avoiding Immune Destruction’; ‘Tumour Promoting
Inflammation’ – Kinase-dependent and -independent functions of
TYK2
Immunity and inflammation are central in the initiation, recog-
nition, elimination or prolongation of cancerous transformations
[126,127]. Historically, Veronika Sexl’s and our labs were the first
to link TYK2 to cancer by transplantable and induced tumours in
LOF mice, which developed haematopoietic malignancies due to
impaired cytotoxicity of NK and T cells [128,129]. Subsequently
we identified an indispensable role of TYK2 in the immune surveil-
lance of adenocarcinoma and T cell lymphoma cells [23,130].Table 2
TYK2’s cell extrinsic and intrinsic involvement in the hallmarks and enabling
characteristics of cancer.
Hallmarks/
characteristics
Cell extrinsic effects
‘Avoiding Immune
Destruction’
 TYK2 LOF in mice leads to impaired surveillance of
B and T cell tumours and of transplantable
tumours
‘Tumour Promoting
Inflammation’
 TYK2 is detrimental in several mouse models of
(auto-) inflammatory diseases
 TYK2 is linked to and causative for several human
(auto-) immune diseases
‘Inducing
Angiogenesis’
 TYK2 is essential in uPA-uPAR signalling
Cell intrinsic effects
‘Activating Invasion
and Metastasis’
 TYK2 is involved in EMT and expression of MMPs
 TYK2 drives invasiveness of various cancer types
‘Deregulating Cellular
Energetics’
 TYK2 is involved in the Warburg effect
 TYK2 is genetically linked to and/or determines
susceptibility to diabetes
‘Resisting Cell Death’  TYK2 induces and/or interacts with pro-apop-
totic factors (e.g. DAXX, SIVA1, TRAIL)
 TYK2 induces anti-apoptotic genes (e.g. Bcl2,
Mcl1)
 TYK2 mediates autophagy (e.g. through STS1)
‘Genome Instability
and Mutations’
 TYK2 interacts with Ku80
‘Enabling Replicative
Immortality’
 TYK2 mutations and fusions are oncogenic
‘Sustaining
Proliferative
Signalling’
 TYK2 mutations and fusions are oncogenic
‘Evading Growth
Suppressors’
 TYK2 mutations and fusions are oncogenic
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inhibitory activity in myeloid-derived suppressor cells keeping
the CTLs in check [131]. Anticancer immunity and cytotoxicity is
largely shaped by cytokines such as type I IFNs and IL-12 which
signal through TYK2 [132–134]. Increasing evidence of kinase-
independent functions of JAKs prompted us to test the hypothesis
that some of the defects in immunity against tumours observed in
Tyk2/ mice are independent of the canonical cytokine signalling
cascades. To this end, we studied cell mediated tumour immuno-
surveillance in mice expressing kinase-inactive TYK2 (Tyk2K923E)
[28]. Canonical, i.e. kinase-dependent TYK2 activity is required
for immunity against viruses in vivo. Moreover, enzyme-inactive
TYK2 phenocopied TYK2 LOF with respect to signalling of type I
IFNs and IL-12 in NK cells [28,130]. However, NK cell mediated
tumour surveillance and cytotoxicity of NK cells remained fully
or partially independent of TYK2 catalytic activity [130]. These
results reveal that a potential use of TYK2 inhibitors for cancer
therapy would not impair the NK cell responses as much as antic-
ipated from studies in LOF mice. Currently we investigate the
molecular mechanisms underlying the anti-tumour response of
TYK2 kinase-inactive NK cells and whether the phenomenon
appears also in other immune cells.
The molecular crossroads between cancer and inflammation
emerged at the beginning of the new millennium [135,136].
Inflammation may contribute by several mechanisms to tumour
development, progression and dissemination by providing growth
factors and cytokines that favour proliferation, invasion, angiogen-
esis and metastasis [137,138]. The involvement of TYK2 in (auto-)
inflammatory pathologies is well established in animal models and
through GWAS pinpointing TYK2 as an important locus (see
above). Currently, the most frequent associations are reported for
colitis and colitis-associated cancers [139,140].5.2. ‘Activating Invasion and Metastasis’; ‘Inducing Angiogenesis’
Epithelial-to-mesenchymal transition (EMT) is a crucial process
facilitating tumour cell invasion and dissemination. Annexin A1
(AnxA1) is frequently downregulated during EMT/metastasis and
knockdown of AnxA1 induces EMT in a TYK2-dependent manner
[141]. Metalloproteinases (MMPs) also contribute to invasion,
metastasis and angiogenesis by degradation of the extracellular
matrix (ECM) [142,143]. In an ischemia/reperfusion (I/R) model
TYK2 was essential for the expression of MMP-2, 9 and 14 in the
intestine [144].
TYK2’s significance in tumour cell dissemination is obviously
context-dependent. In an El-Myc transgenic mouse model for
human Burkitt’s lymphoma, Tyk2-deficient mice show reduced
invasiveness of malignant cells [145]. A similar phenotype was
observed with human prostate and breast cancer cells, where inhi-
bition of TYK2 reduced cancer cell invasiveness [57,146]. Hence
blocking TYK2 might be an effective therapeutic approach to pre-
vent metastasis. In contrast, TYK2 is frequently downregulated in
estrogen receptor alpha (ERa) negative human breast cancer sam-
ples during metastasis to the regional lymph node [147].
Angiogenesis is essential to provide the progressive tumour
with nutrients and oxygen and involves processes like proteolysis,
migration and degradation of the ECM which enable cancer cell
invasiveness. The urokinase type plasminogen activator (uPA)
and its receptor uPAR coordinate ECM proteolysis and activate sig-
nalling pathways leading to cell migration, proliferation and sur-
vival [148]. Notably the uPA–uPAR system plays an important
role in angiogenesis [149]. Several reports have shown that TYK2
is essential in mediating the uPA–uPAR induced signalling in vas-
cular smooth muscle cells (VSMCs) and glomerular mesangial cells
(MCs) [150–155].ant of tumours and bona fide oncogene, Cytokine (2015), http://dx.doi.org/
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Analogous to the insight into the molecular communalities
between cancer and inflammation a decade ago, recent reports
show that the cellular responses upon carcinogenesis and infection
share many common features and lead to metabolic changes, best
exemplified by aerobic glycolysis also referred to as Warburg effect
[124,156,157]. We showed in an early study that TYK2 is required
to switch cellular glucose and lipid metabolism during innate
immune responses [158]. A comprehensive study suggests that
TYK2 dysregulation or LOF leads to obesity [159]. Later, GWAS
has linked TYK2 to diabetes susceptibility (see above).
5.4. ‘Enabling Replicative Immortality’
It is undisputed that cancer cells require unlimited replicative
potential in order to form tumours. This capacity centrally involves
telomere length and telomerase activity. Non-immortalised cells
show almost absent telomerase, hence cell division leads to pro-
gressive telomere shortening, which in turn eventually induces
senescence and apoptosis. Immortalised cells in contrast express
telomerase at functionally significant levels and allow for exten-
sion of telomeric DNA [160,161]. Telomerase expression is com-
plex regulated by several transcription factors that are induced
by intracellular and extracellular signalling pathways. The multi-
step molecular regulation of telomerase for differing cell types
has to be rigorously elucidated. At least for the development of
haematopoietic cancers a cytokine dependent involvement of the
JAK–STAT pathway is evident [162]. A specific function of TYK2
remains to be reported.
5.5. ‘Resisting Cell Death’
Preventing apoptosis is a key feature of tumour cells. IFNs are
important regulators of apoptosis that induce expression of pro-
or anti-apoptotic genes and disturbed IFN signalling may have fatal
effects on cell survival [163,164]. Indeed, the induction of local or
tumour-associated IFN-I production is discussed as promising
strategy for the induction of cell death [165]. Several studies
emphasized the implication of TYK2 in pro- as well as anti-
apoptotic actions. TYK2 is required for type I IFN induced apoptosis
in primary pro-B cells and pancreatic cells [110,166,167]. TYK2 is
also essential in IFNa induced B lymphocyte growth arrest or apop-
tosis by the induction of and/or interaction with pro-apoptotic fac-
tors [168,169]. In neuronal cells TYK2 is required for b-amyloid
(Ab) induced cell death [170]. TYK2 induces tumour necrosis factor
(TNF) related apoptosis inducing ligand (TRAIL) in fibrosarcoma
cells [171]. In osteosarcoma cell lines TYK2 has been shown to
drive the expression of anti-apoptotic genes like B-cell CLL/lym-
phoma 2 (BCL2) and myeloid cell leukaemia 1 (MCL1). Further-
more, TYK2 is necessary for cell survival upon fibroblast growth
factor (FGF2) signalling [172].
Autophagymay be beneficial or deleterious for tumour cells and
IFNs can trigger autophagy [173]. Suppressor of T-cell receptor sig-
nalling 1 (STS1) engages the IFNAR/TYK2 axis to induce autophagy
in B cells [174].
5.6. ‘Genome Instability and Mutation’
Mutational signatures of cancer genomes are informative con-
cerning the history and the prognosis of the cancer. The identifica-
tion of mutational processes may give rise to stratified anticancer
therapies [175,176]. Various components of the DNA repair
machinery are regulated by transcriptional or post-translational
signalling circuits [177]. Recently, type I IFN was found to be
directly induced by cytosolic sensing of DNA damage therebyPlease cite this article in press as: N.R. Leitner et al., Tyrosine kinase 2 – Surveill
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TYK2 an IFN-induced interaction with Ku80 has been reported
[180]. The heterodimer Ku70/Ku80 is the main double strand
repair pathway in mammals [181]. JAK–STAT signalling is not only
involved in the induction and/or activation of the DNA repair mole-
cules but in Drosophila the axis itself was found to remodel chro-
matin and thereby to stabilise genome regions [182]. Nuclear
and chromatin remodelling functions have also been described
for mammalian JAKs [183], an exciting field currently intensively
investigated.
5.7. ‘Sustaining Proliferative Signalling’; ‘Evading Growth Suppressors’
– TYK2 mutants and fusion proteins in cancers
Cancer cells are most fundamentally characterised by their
capability to continuously proliferate. This is typically achieved
by gain-of-function (GOF) mutations of proto-oncogenes, LOF of
tumour suppressors, loss of negative feedback mechanisms and
contact inhibition, GOF mutations of transcription factors and
many other mechanisms. Tumour-specific expression or activation
profiles of TYK2 have been observed in various cancer types
[146,147,184–186]. Reports on mutated and hyperactive TYK2 or
inactive TYK2, i.e. oncogenic TYK2 were missing until recently.
We screened the COSMIC (catalogue of somatic mutations in
cancer; http://cancer.sanger.ac.uk/cosmic) database, which
describes over two million coding point mutations in over one mil-
lion tumour samples across human genes [187,188]. Although over
230 mutations in the TYK2 gene were reported in the database in
Q2/2015, this number is far too low for pointing towards accumu-
lating mutations across TYK2, as turned out to be the case for the
mutational hotspot in the JH2 domain of JAK2. Nevertheless, the
reports on cancer-associated TYK2 mutations increase rapidly
[189]. Screening samples from patients suffering from breast or
gastrointestinal cancers and acute myeloid leukaemia (AML) a
common missense mutation (TYK2P1104A) was identified
[190,191]. The mutation is located in the substrate-binding groove
of the kinase domain and leads to decreased TYK2 phosphorylation
upon IFNa stimulation. Nine additional TYK2 SNPs associated to
AML have been described (see Fig. 1) [191]. TYK2V362F emerged
also in a screening of 254 established cell lines from brain and
haematopoietic tumours [192] as well as in GWAS linking TYK2
to SLE [98]. The first activating (GOF) TYK2 mutations were
reported in 2013 by a team headed by A. Thomas Look [193].
Screening of T cell acute lymphoblastic leukaemia (T-ALL) cell lines
revealed five variants leading to increased tyrosine phosphoryla-
tion of TYK2 (G36D, S47N, V731I, E957D and R1027H in the FERM,
the SH2 and the kinase domain; see Fig. 1). The survival of the
patient-derived T-ALL cells and of the investigated cell lines was
dependent on TYK2 and STAT1. Blocking of TYK2 by inhibitors
reduced cell growth in several T-ALL cell lines and primary speci-
mens. This publication drew the community’s attention to TYK2
as a potential oncogene and target for therapeutic kinase inhibi-
tors. All so far identified GOF or LOF and experimentally induced
mutations of TYK2 are depicted in Fig. 1.
Equally exciting are the recent reports on TYK2 genomic rear-
rangements identified in three different studies engaging whole
genome/transcriptome analysis of patients diagnosed with mature
T-cell neoplasms or acute lymphoblastic leukaemia [194–196].
RNA sequencing of a cutaneous T-cell lymphoma-derived cell line
revealed a fusion of the 50 region of the nucleophosmin gene
(NPM1) with the 30 region of TYK2 including a part of the pseudok-
inase and the complete kinase domain [196] (see Fig. 2). Extending
the study to analysis of a large cohort of mature T-cell lymphopro-
liferative disorders revealed TYK2 rearrangements in 15% of CD30+
lymphoproliferative disorders (LPDs), amongst them 20% of
patients diagnosed with lymphomatoid papulosis (LYP) andant of tumours and bona fide oncogene, Cytokine (2015), http://dx.doi.org/
Fig. 2. TYK2 fusion proteins in ALCL and Ph-like ALL. TYK2 fusion proteins with NPM1 (LYP, PC-ALCL), NFKB2 (ALK ALCL), PABPC4 (ALK ALCL) and MYB (Ph-like ALL). Fused
protein domains in their relative size are shown on top. Gene structures with translated exons (filled boxes) are indicated below. Please note that in accordance with [194] we
used exon numbering referring to translated exons, while exon nos. of NPM1-TYK2 and MYB-TYK2 indicated in the original papers [195,196] include non-translated exons.
TYK2 domains are indicated: PK (pseudokinase domain) and K (kinase domain). Oncogenic potential has been experimentally shown for NPM1-TYK2 and NFKB-TYK2.
6 N.R. Leitner et al. / Cytokine xxx (2015) xxx–xxx12.5% with primary cutaneous anaplastic large cell lymphoma
(PC-ACLC). In total two patients (one LYP and one cutaneous ACLC)
carried the described NPM1-TYK2 fusion, whereas the other 5
identified TYK2 rearrangements were not described further.
Detailed analysis of the NPM1-TYK2 fusion protein revealed a con-
stitutive TYK2 activation as shown by phosphorylation of Y1054/
Y1055. Interestingly, the subcellular distribution showed that
NPM1-TYK2 was localized predominantly in the nucleus. As a con-
sequence of constitutively activated TYK2 also the downstream
effectors STAT1, 3 and 5 were constitutively activated by phospho-
rylation of the respective tyrosine residues. Ectopic expression of a
FLAG-tagged NPM1-TYK2 fusion in a HEK293 cell line led to consti-
tutive phosphorylation of TYK2 and STAT1, 3 and 5. This could not
be observed when using a kinase-dead TYK2 fusion protein
(TYK2K462R). Knockdown of the TYK2 fusion protein by specific
small hairpin (sh) RNAs in leukaemic cells led to decreased phos-
phorylation of STATs and decreased cell proliferation, suggesting
that TYK2 is an oncogenic driver kinase.
The second report discovered TYK2 fusion proteins in patients
diagnosed with anaplastic large cell lymphoma (ALCL) [194].
RNA-Seq of anaplastic lymphoma kinase (ALK)+/ALK ALCL
patients identified 28 fusion proteins amongst them two engaging
the C-terminal portion of TYK2. In one case the coding region of
exons 1–8 of poly(A) binding protein cytoplasmatic 4 (PABPC4)
was fused to exons 14–23 of TYK2 (PABPC4-TYK2) (see Fig. 2). The
other case exhibited a fusion of exons 1–16 of nuclear factor of
kappa light polypeptide gene enhancer in B cells 2 (NFKB2) to
exons 16–23 of TYK2 (NFKB2-TYK2) (see Fig. 2). Ectopic expression
of NFKB2-TYK2 in a HEK293 cell line led to constitutive phospho-
rylation of TYK2, JAK2 and STAT3, which was absent when usingPlease cite this article in press as: N.R. Leitner et al., Tyrosine kinase 2 – Surveill
10.1016/j.cyto.2015.10.015a kinase-dead version of NFKB2-TYK2. The TYK2 fusion protein
was localized in both, nucleus and cytoplasm. The oncogenic activ-
ity of the fusion protein was proven by transfection of NFKB2-TYK2
into mouse 3T3 fibroblasts, which resulted in a larger number of
colonies than in control cells. Interestingly, Stat3/murine embry-
onic fibroblasts (MEF) showed only a slight increase in colonies
after transfection of NFKB2-TYK2, suggesting that STAT3 is required
for the oncogenic activity of NFKB2-TYK2. Finally the authors
revealed that constitutive phosphorylation of STAT1, 3 and 5 could
be inhibited by a selective JAK/TYK2 inhibitor and by a specific
shRNA when NFKB2-TYK2 was expressed ectopically in MEFs and
Jurkat cells.
Finally another genomic rearrangement of TYK2 was observed
in a patient with Philadelphia chromosome-like acute lymphoblas-
tic leukaemia (Ph-like ALL, also called BCR–ABL1-like ALL). Whole
genome and transcriptome sequencing of a cohort of Ph-like ALL
patients revealed genomic rearrangements resulting in activated
kinase signalling in 96 out of 154 patients [195]. One novel TYK2
fusion protein was identified as a result of a rearrangement of
v-myb avian myeloblastosis viral oncogene homolog (MYB) and
TYK2. As noted in the two studies described above the TYK2 fusion
protein contains a part of the pseudokinase domain and the com-
plete kinase domain (see Fig. 2). Although the authors do not pro-
vide any functional analyses, it may be speculated that TYK2 is
constitutively active in this case as well and that activated down-
stream effectors drive the oncogenic activity. Further data on addi-
tional patient cohorts and functional analysis of the fusion protein
(s) and the activating mutations of TYK2 will further clarify the
molecular mechanisms and the frequency of the mutations in
leukaemias and other cancers.ant of tumours and bona fide oncogene, Cytokine (2015), http://dx.doi.org/
N.R. Leitner et al. / Cytokine xxx (2015) xxx–xxx 76. Summary and outlook
In addition to the well-known function of TYK2 in (auto-)
inflammation and immunity to infection and cancers, the recent
cancer landscape NGS data revealed the oncogenic potential of
TYK2 either as fusion or mutated protein.
Working with TYK2 for over two decades sometimes raised the
doubt whether TYK2 is a ‘respectable’ member of the JAK kinase
family for the following reasons: it was cloned and named differ-
ently from JAK1-3; its LOF phenotype is relative subtle compared
to the other JAKs; its reported germline or somatic mutations in
cancer settings were sparse compared to a plethora of driver muta-
tions in JAK1-3. Now it seems that TYK2 has joined the club of the
’real ones’: the function of TYK2 has expanded from an efficient
surveillant of tumours to a bona fide oncogene. Future work will
have to show whether the identified activating TYK2 amino acids
exchanges and TYK2 fusion proteins are frequent driver or passen-
ger mutations and whether TYK2 inhibitors are efficient anticancer
drugs in addition to their current development to treat autoim-
mune diseases [79,197,198].
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